Jul 14, 2015 7:35am EDT Matinas BioPharma Announces Two Abstracts Accepted for Presentation on Preclinical Data of Lead Anti-Infective Product Candidates MAT2203 and MAT2501 at ICAAC/ICC 2015
Jul 07, 2015 7:35am EDT Matinas BioPharma to Present at the 12th Anti-Infectives Partnering and Deal Making Conference
Jun 15, 2015 7:05am EDT Matinas BioPharma's MAT9001 Demonstrates Superiority in Reducing Triglycerides, Lipids, Apolipoproteins and PCSK9 Levels in Head-to-Head Study With Vascepa(R)
Jun 10, 2015 7:35am EDT Matinas BioPharma to Present at the BIO International Convention on June 18, 2015
Jun 04, 2015 7:05am EDT Matinas BioPharma Announces Acceptance of Late-Breaking Abstract on MAT9001 Comparative Study Results Versus Vascepa(R) for Poster Presentation at the National Lipid Association Scientific Sessions
Jun 01, 2015 8:00am EDT Matinas BioPharma's MAT9001 Meets Primary and Secondary Endpoints in First Human Trial versus Vascepa(R)
May 26, 2015 7:35am EDT Matinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
Apr 07, 2015 8:05am EDT Matinas BioPharma to Present at the 2nd Annual Growth Capital Expo on April 13, 2015
